Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Infections | 14 | 2021 | 11620 | 0.94 | Why? |
| Carotid Intima-Media Thickness | 2 | 2017 | 179 | 0.76 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 139 | 0.75 | Why? |
| Lipodystrophy | 1 | 2017 | 18 | 0.72 | Why? |
| Sofosbuvir | 2 | 2020 | 518 | 0.70 | Why? |
| Anti-HIV Agents | 4 | 2018 | 2209 | 0.69 | Why? |
| Cyclohexanes | 1 | 2017 | 43 | 0.66 | Why? |
| Vasculitis, Central Nervous System | 1 | 2018 | 97 | 0.64 | Why? |
| Carbamates | 1 | 2020 | 485 | 0.63 | Why? |
| Multimorbidity | 1 | 2019 | 703 | 0.53 | Why? |
| Triazoles | 1 | 2017 | 440 | 0.48 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 529 | 0.45 | Why? |
| Dyslipidemias | 1 | 2017 | 791 | 0.42 | Why? |
| Tenofovir | 4 | 2018 | 449 | 0.42 | Why? |
| Hyperglycemia | 4 | 2021 | 1363 | 0.39 | Why? |
| Cardiovascular Diseases | 5 | 2019 | 11497 | 0.38 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.36 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 1510 | 0.36 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.33 | Why? |
| Lipids | 3 | 2018 | 1079 | 0.32 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2019 | 260 | 0.29 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.29 | Why? |
| Adenine | 2 | 2018 | 463 | 0.28 | Why? |
| Integrase Inhibitors | 2 | 2018 | 27 | 0.23 | Why? |
| Brain | 2 | 2018 | 5133 | 0.22 | Why? |
| Alkynes | 2 | 2018 | 98 | 0.22 | Why? |
| Hypertension | 5 | 2021 | 8895 | 0.22 | Why? |
| Benzoxazines | 2 | 2018 | 103 | 0.21 | Why? |
| DNA-Directed DNA Polymerase | 1 | 2020 | 47 | 0.21 | Why? |
| Turbinates | 1 | 2021 | 205 | 0.21 | Why? |
| Blood Pressure | 3 | 2020 | 2198 | 0.20 | Why? |
| HIV-Associated Lipodystrophy Syndrome | 1 | 2018 | 15 | 0.19 | Why? |
| Calcaneus | 1 | 2018 | 13 | 0.18 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.18 | Why? |
| Growth Hormone-Releasing Hormone | 1 | 2017 | 17 | 0.18 | Why? |
| CD4 Lymphocyte Count | 3 | 2020 | 1517 | 0.18 | Why? |
| Cyclopropanes | 2 | 2018 | 332 | 0.18 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.18 | Why? |
| Italy | 12 | 2020 | 38444 | 0.17 | Why? |
| Bone Diseases, Metabolic | 1 | 2018 | 64 | 0.17 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2018 | 275 | 0.17 | Why? |
| Athetosis | 1 | 1996 | 1 | 0.17 | Why? |
| Chorea | 1 | 1996 | 13 | 0.17 | Why? |
| Toxoplasmosis, Cerebral | 1 | 1996 | 12 | 0.17 | Why? |
| Personality Disorders | 1 | 2017 | 81 | 0.16 | Why? |
| CCR5 Receptor Antagonists | 1 | 2017 | 66 | 0.16 | Why? |
| Brachial Artery | 1 | 2017 | 107 | 0.16 | Why? |
| Organophosphonates | 1 | 2017 | 85 | 0.16 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2017 | 107 | 0.16 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.16 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.16 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.16 | Why? |
| Cobicistat | 1 | 2017 | 172 | 0.16 | Why? |
| AIDS Dementia Complex | 1 | 1996 | 48 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| Lamivudine | 1 | 2017 | 210 | 0.15 | Why? |
| HIV | 2 | 2019 | 1116 | 0.14 | Why? |
| Atazanavir Sulfate | 1 | 2017 | 213 | 0.14 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| Vasodilation | 1 | 2017 | 258 | 0.14 | Why? |
| Drug Therapy, Combination | 5 | 2020 | 7268 | 0.14 | Why? |
| Delphi Technique | 1 | 2019 | 1257 | 0.14 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.13 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.13 | Why? |
| Diabetes Mellitus | 3 | 2021 | 8207 | 0.13 | Why? |
| HIV-1 | 3 | 2018 | 3365 | 0.13 | Why? |
| Darunavir | 1 | 2017 | 477 | 0.13 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.12 | Why? |
| Metabolic Syndrome | 1 | 2021 | 810 | 0.12 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.12 | Why? |
| Osteoporosis | 1 | 2018 | 410 | 0.12 | Why? |
| Violence | 1 | 2017 | 534 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2020 | 995 | 0.11 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2018 | 665 | 0.11 | Why? |
| Insulin | 1 | 2020 | 1316 | 0.11 | Why? |
| Cluster Analysis | 1 | 2019 | 3001 | 0.11 | Why? |
| Neuroimaging | 1 | 2018 | 1106 | 0.10 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.10 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.10 | Why? |
| Inflammation Mediators | 2 | 2020 | 2654 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.09 | Why? |
| Middle Aged | 15 | 2020 | 270681 | 0.08 | Why? |
| Hypoglycemic Agents | 1 | 2020 | 2165 | 0.08 | Why? |
| Data Collection | 1 | 2017 | 1769 | 0.08 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.08 | Why? |
| Humans | 28 | 2021 | 930598 | 0.08 | Why? |
| Schizophrenia | 1 | 2017 | 1018 | 0.08 | Why? |
| Pyrazines | 1 | 2017 | 1783 | 0.08 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2017 | 1671 | 0.08 | Why? |
| Oxazines | 2 | 2018 | 279 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.08 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.08 | Why? |
| Endothelium, Vascular | 1 | 2017 | 1751 | 0.07 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.07 | Why? |
| Risk Factors | 7 | 2020 | 71621 | 0.07 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Ritonavir | 2 | 2018 | 4212 | 0.07 | Why? |
| Male | 16 | 2020 | 367725 | 0.07 | Why? |
| Neurologic Examination | 2 | 2020 | 428 | 0.07 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Female | 16 | 2020 | 380317 | 0.07 | Why? |
| Liver Diseases | 1 | 2020 | 2698 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.07 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
| Longitudinal Studies | 2 | 2017 | 9893 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Piperazines | 2 | 2018 | 445 | 0.07 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.07 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| Adult | 11 | 2020 | 244371 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Pyridones | 2 | 2018 | 738 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3832 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.06 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.06 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.05 | Why? |
| Cohort Studies | 3 | 2019 | 36005 | 0.05 | Why? |
| Gangliosides | 1 | 2020 | 86 | 0.05 | Why? |
| Spinal Puncture | 1 | 2020 | 95 | 0.05 | Why? |
| Radiculopathy | 1 | 2020 | 79 | 0.05 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.05 | Why? |
| Diagnostic Equipment | 1 | 2019 | 41 | 0.05 | Why? |
| Aged | 7 | 2020 | 215776 | 0.05 | Why? |
| Blood Coagulation Factors | 1 | 2020 | 223 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.04 | Why? |
| Leukocytosis | 1 | 2020 | 280 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.04 | Why? |
| Nerve Tissue Proteins | 1 | 2020 | 319 | 0.04 | Why? |
| Maximum Tolerated Dose | 1 | 2017 | 65 | 0.04 | Why? |
| Dominance, Cerebral | 1 | 1996 | 2 | 0.04 | Why? |
| Sulfadiazine | 1 | 1996 | 8 | 0.04 | Why? |
| Pyrimethamine | 1 | 1996 | 18 | 0.04 | Why? |
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 184 | 0.04 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.04 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.04 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.04 | Why? |
| Brain Mapping | 1 | 1996 | 228 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.04 | Why? |
| Bone Density | 1 | 2018 | 335 | 0.04 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2019 | 53120 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Antibodies | 1 | 2020 | 846 | 0.03 | Why? |
| Lipid Metabolism | 1 | 2018 | 572 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Encephalitis | 1 | 2020 | 797 | 0.03 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.03 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2019 | 1425 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.03 | Why? |
| Delirium | 1 | 2020 | 1061 | 0.03 | Why? |
| Membrane Proteins | 1 | 2020 | 1733 | 0.02 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.02 | Why? |
| Safety | 1 | 2017 | 1583 | 0.02 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Blood Coagulation | 1 | 2020 | 2768 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 1996 | 3776 | 0.02 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.02 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.02 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.02 | Why? |
| Blood Glucose | 1 | 2020 | 3642 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 1996 | 1766 | 0.02 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Protease Inhibitors | 1 | 2018 | 3630 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Alanine | 1 | 2018 | 5687 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2019 | 43792 | 0.01 | Why? |